Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with
topotecan as second-line treatment for patients with extensive stage small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences